{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:52Z","timestamp":1786119412497,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/cad.0b013e3283324d83","type":"journal-article","created":{"date-parts":[[2009,12,4]],"date-time":"2009-12-04T03:19:07Z","timestamp":1259896747000},"page":"101-106","source":"Crossref","is-referenced-by-count":21,"title":["Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial"],"prefix":"10.1097","volume":"21","author":[{"given":"Sisto","family":"Perdon\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cantiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"De Sio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Masala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Quattrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Pizzuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Autorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210203","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"R2-11-20210203","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille calmette-guerin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"R3-11-20210203","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus calmette-guerin versus mitomycin c for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"R4-11-20210203","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"R5-11-20210203","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"R6-11-20210203","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumours who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"},{"key":"R7-11-20210203","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumours","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"R8-11-20210203","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder","volume":"54","author":"Babjuk","year":"2008","journal-title":"Eur Urol"},{"key":"R9-11-20210203","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00042307-200409000-00005","article-title":"Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures","volume":"14","author":"Joudi","year":"2004","journal-title":"Curr Opin Urol"},{"key":"R10-11-20210203","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cncr.23137","article-title":"Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience","volume":"112","author":"Perdon\u00e0","year":"2008","journal-title":"Cancer"},{"key":"R11-11-20210203","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1517\/14656566.8.18.3251","article-title":"Gemcitabine in bladder cancer","volume":"8","author":"El","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R12-11-20210203","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1464-410X.2005.05739.x","article-title":"Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option","volume":"96","author":"Gontero","year":"2005","journal-title":"BJU Int"},{"key":"R13-11-20210203","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus calmette-guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"R14-11-20210203","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille calmette-gu\u00e9rin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"R15-11-20210203","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"R16-11-20210203","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumours of the bladder: international consensus panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"R17-11-20210203","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"R18-11-20210203","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle invasive bladder cancer: difference between primary and progressive tumours: possible implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"R19-11-20210203","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"R20-11-20210203","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0090-4295(97)00510-4","article-title":"Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille calmette-guerin","volume":"5","author":"Sarosdy","year":"1998","journal-title":"Urology"},{"key":"R21-11-20210203","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer","volume":"172","author":"O'Donnell","year":"2004","journal-title":"J Urol"},{"key":"R22-11-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"Van Der Heijden","year":"2004","journal-title":"Eur Urol"},{"key":"R23-11-20210203","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/S0022-5347(05)66239-8","article-title":"Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer","volume":"165","author":"Waidelich","year":"2001","journal-title":"J Urol"},{"key":"R24-11-20210203","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus calmette-guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"R25-11-20210203","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1464-410X.2009.08543.x","article-title":"A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Gu\u00e9rin therapy","volume":"104","author":"Barlow","year":"2009","journal-title":"BJU Int"},{"key":"R26-11-20210203","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"R27-11-20210203","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000090870","article-title":"Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study","volume":"76","author":"Gacci","year":"2006","journal-title":"Urol Int"},{"key":"R28-11-20210203","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6604074","article-title":"Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study","volume":"97","author":"Gunelli","year":"2007","journal-title":"Br J Cancer"},{"key":"R29-11-20210203","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000089164","article-title":"Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Gu\u00e9rin therapy","volume":"75","author":"Bassi","year":"2005","journal-title":"Urol Int"},{"issue":"5","key":"R30-11-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdj966","article-title":"Actual experience and future development of gemcitabine in superficial bladder cancer","volume":"17","author":"Gontero","year":"2006","journal-title":"Ann Oncol"},{"key":"R31-11-20210203","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.mou.0000240310.70582.ce","article-title":"Intravesical gemcitabine: an update of clinical results","volume":"16","author":"Hendricksen","year":"2006","journal-title":"Curr Opin Urol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e3283324d83","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:01Z","timestamp":1786039861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201001000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3283324d83","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}